(XGN) Exagen Inc. Business Model Canvas Research

Health plans and other reimbursement stakeholders shape whether Exagen Inc. tests are covered and paid, so the company must match evidence, coding, and prior-authorization docs to each payer’s rules. Reimbursement support is a core partnership need in diagnostics because it directly affects test access, order volume, and cash collection.

• Coverage rules drive test access
• Evidence must fit payer policy
• Reimbursement support protects revenue

Exagen Inc. depends on reagent, equipment, and platform suppliers for the lab materials and testing systems behind its CB-CAPs-based assays and biomarker panels. Supplier continuity matters because any interruption can affect test quality, throughput, and the ability to scale volume without delays.

• Supports CB-CAPs assay inputs
• Covers biomarker panel infrastructure
• Protects quality and scale

Exagen Inc. centers reimbursement and claims support on getting paid for its tests, using payer evidence, coding support, and follow-up on denied claims. For a diagnostics Company Name, this is a core commercial task because reimbursement performance directly shapes test adoption, cash collection, and revenue conversion.

• Secure payer coverage and payment
• Support coding and claim submission
• Chase denials and underpayments
• Protect commercial execution quality

Exagen Inc.'s sales and account management teams drive use in rheumatology accounts by helping clinics with ordering, training, and fast issue resolution. That support keeps workflows smooth, sustains repeat testing, and helps retain accounts.

• Boosts rheumatology account utilization
• Supports ordering and training
• Resolves issues fast
• Drives repeat testing and retention

Exagen Inc.'s laboratory infrastructure and quality systems are core resources because regulated lab operations are needed to produce reliable autoimmune test results. Workflow controls, QC checks, and reporting systems support scale and FDA/CLIA compliance, which helps keep turnaround stable as volume grows.

• Regulated lab operations
• Quality control and reporting
• Scalable, compliant workflows

Exagen Inc. relies on scientific, medical, and regulatory talent to design autoimmune tests, support clinicians, and keep claims credible. For a diagnostics company, this is core IP: the staff that bridges R&D, medical affairs, and FDA-facing work helps protect adoption, reimbursement, and trust.

• Builds and validates test performance.
• Supports clinician education and use.
• Maintains regulatory and medical credibility.

Exagen Inc.’s value is breadth: one menu spans 4 autoimmune areas—SLE, RA, APS, and ANCA-associated vasculitis—plus monitoring tools like Anti-CarP, PC4d, MTX, and HCQ. That lets clinicians follow patients over time, not just make a one-off call, which is a real edge in longitudinal autoimmune care.

• 4 disease areas covered
• Longitudinal care support
• Biomarker and drug monitoring

AVISE SLE Monitor and AVISE HCQ help Exagen Inc. move beyond one-time diagnosis to ongoing care, tracking disease activity and hydroxychloroquine use so clinicians can adjust treatment with real, actionable results. That matters because lupus care is long-term, and monitoring tools can support faster decisions when symptoms shift.

• Tracks disease activity over time

• Checks hydroxychloroquine use

• Supports treatment changes, not just diagnosis

Exagen Inc. keeps customer ties through account-based commercial management: teams track test utilization, fix ordering or billing issues, and support clinic and lab workflows. In B2B diagnostics, this is the core of retention because each account needs steady service, payer support, and fast problem resolution.

• Ongoing account management
• Utilization monitoring and support
• Ordering-process issue resolution

Autoimmune disease care is long term, so Exagen Inc.’s tests can be used for serial monitoring and follow-up with the same clinical accounts. In the U.S., about 50 million people live with autoimmune disease, which supports recurring testing rather than one-off use.

• Supports repeat monitoring over time
• Builds recurring clinic-level relationships

Exagen Inc. uses company websites and online materials to teach physicians about AVISE tests, including indications, panel choices, and how to read results; this supports field sales and medical education. In 2025, Exagen reported $48.5 million in net revenue, and digital channels help scale education across a national physician base without adding much fixed cost.

• Explains test use and result interpretation
• Supports sales reps and MSL outreach
• Scales education at low marginal cost

Scientific conferences and peer-reviewed publications let Exagen Inc. reach rheumatologists and lab specialists with data they trust. In evidence-driven diagnostics, this matters because medical adoption is shaped by published clinical validation, and Exagen’s 2025 filings show the company still depends on proof-based demand, not mass-market ads.

These channels build credibility by showing test performance, clinical utility, and physician-led interpretation at congresses and in journals. They are one of Exagen Inc.’s strongest routes to specialty adoption, because one strong paper or conference presentation can influence many prescribers at once.

• Reach specialists through congresses and journals
• Build trust with peer-reviewed clinical evidence
• Support adoption in evidence-driven diagnostics

Integrated and group rheumatology practices are a core Exagen Inc. customer segment because one account can generate repeated AVISE test volume across multiple physicians. They also need fast ordering, clear results reporting, and reimbursement help, since these workflows drive adoption and commercial scale.

• Repeat volume from many physicians
• Simple ordering and reporting
• Strong reimbursement support
• Key driver of scale

Patients with chronic autoimmune disease need serial checks over time, so Exagen Inc. can serve them with repeat use of 3 core tools: SLE Monitor, HCQ, and MTX monitoring. This segment drives recurring diagnostic demand as care teams track disease activity and treatment use across many visits.

• Serial assessment over time
• 3 tests support repeat use
• Recurring diagnostic demand

Exagen Inc., based in Vista, California, carries fixed overhead for headquarters, finance, HR, and compliance, plus scientific, operational, commercial, and admin staff. In 2025, this labor-heavy model made staffing and lab utilization the main cost drivers, so payroll discipline matters more than top-line growth.

• Vista HQ adds fixed corporate costs
• Needs scientific, ops, commercial staff
• Staffing drives SG&A and R&D spend

Compliance, quality, and reimbursement administration are a real cost center for Exagen Inc., because diagnostics firms must fund quality systems, payer documentation, and claims support to protect revenue and keep test credibility high. In 2025, these controls mattered even more as U.S. diagnostic pricing stayed under payer review and every denied claim had to be reworked or appealed.

• Funds QA and regulatory controls
• Supports claims and payer docs
• Reduces denials and revenue leakage

Exagen Inc.'s specialty autoimmune panel sales expand revenue per patient by bundling AVISE CTD, Lupus, APS, Vasculitis AAV, Anti-CarP, and PC4d into one menu. The broad panel supports repeat and cross-sell use across the same referral base, which helps lift test mix and reduces dependence on a single assay.

• Multiple tests from one patient
• Cross-sell inside one autoimmune workup
• Broader menu supports recurring demand

Exagen Inc.'s AHN Research Institute deal can add non-test revenue through collaboration fees, milestones, and possible royalties, so it is useful even if it stays well below routine diagnostics. This stream is strategically important because it diversifies income and can scale if the partnered science advances.

• Non-test revenue from AHN collaboration
• Milestones may lift near-term cash
• Royalties depend on contract terms
• Smaller than diagnostic test sales